Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies

Abstract

The Prostate Cancer Research Program at Weill Cornell Medicine (WCM) and New York-Presbyterian (NYP) is an internationally recognized prostate cancer (PC) clinical and translational research program. In 2017, we were awarded a Specialized Programs of Research Excellence (SPORE) grant in PC, highlighting the depth and breadth of our research. Since joining the Prostate Cancer Clinical Trials Consortium (PCCTC) as a Clinical Research Site in 2014, WCM has brought multiple high-impact and innovative therapeutic and biomarker studies to the PCCTC; enrolled more than 100 patients on clinical trials including 56 this past year; collected, processed, and analyzed over 500 tumor biopsy specimens, circulating tumor cells, and plasma and serum samples in a regulatory-compliant manner; complied with consortium-developed quality assurance and quality control procedures; and led PC advocacy initiatives within the PCCTC. We are expanding our site to include NYP Brooklyn Methodist Hospital (NYPBMH) and Columbia University Medical Center (CUMC).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1163330

Entities

People

  • David Nanus

Organizations

  • Cornell University

Tags

DTIC Thesaurus Topics

  • African Americans
  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Blood
  • Cells
  • Clinical Trials
  • Data Analysis
  • Department Of Veterans Affairs
  • Health Services
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • New York
  • Oncology
  • Prostate Cancer
  • Social Media
  • Therapy
  • United States

Fields of Study

  • Medicine

Readers

  • Oncology
  • Oncology and Biomarker-Based Cancer Detection.
  • Research Science/Academic Research